Results 41 to 50 of about 2,403,288 (173)
ABSTRACT Introduction Hepatocellular carcinoma (HCC) remains a major cause of cancer‐related mortality worldwide, and postoperative recurrence continues to limit long‐term survival. Liver‐resident natural killer (NK) cells are key effectors of antitumor immunity in the hepatic microenvironment. Interleukin‐37 (IL‐37), an anti‐inflammatory cytokine, has
Yuki Imaoka +10 more
wiley +1 more source
Chronic myeloid leukemia stem cells display alterations in expression of genes involved in oxidative phosphorylation [PDF]
The mitochondrial respiratory chain (MRC) consists of protein complexes I, II, III, IV and V that support oxidative phosphorylation (OXPHOS), which depends on electron transport to generate adenosine triphosphate (ATP).
Flis, Krzysztof +9 more
core +1 more source
A meso‐carboxamide‐substituted BODIPY fluorescent probe reports myeloperoxidase (MPO) activity via electrophilic chlorination by MPO‐derived HOCl, generating a highly emissive chlorinated product with a ca. 40 nm bathochromic shift. Applications in quantitative MPO assays, cellular imaging of MPO‐derived HOCl, redox‐dependent discrimination of cancer ...
Siyoung Cho +3 more
wiley +2 more sources
Cross‐Platform Comparison of Chemoproteomics Workflows: Orbitrap‐TMT Versus timsTOF‐diaPASEF
ABSTRACT Chemoproteomics aims to achieve precise and comprehensive quantification of protein–small molecule interactions, yet methodological comparisons across quantitative proteomics workflows remain scarce. Here, we systematically benchmark tandem mass tag data‐dependent acquisition (TMT‐DDA) on Orbitrap Exploris/Eclipse instruments against label ...
Ursula M. Glocker +7 more
wiley +1 more source
Bcr/Abl Interferes with the Fanconi Anemia/BRCA Pathway: Implications in the Chromosomal Instability of Chronic Myeloid Leukemia Cells [PDF]
Chronic myeloid leukemia (CML) is a malignant clonal disorder of the hematopoietic system caused by the expression of the BCR/ABL fusion oncogene. Although it is well known that CML cells are genetically unstable, the mechanisms accounting for this ...
Valeri, Antonio +71 more
core +2 more sources
ABSTRACT Prior pharmacokinetic (PK) analysis revealed that increased alpha‐1‐acid glycoprotein (AAG) levels are associated with decreased imatinib unbound fraction in coronavirus disease 2019 (COVID‐19) patients. This study aimed to investigate the PK of total and unbound concentrations of imatinib and the metabolite N‐desmethyl imatinib in ...
Medhat M. Said +10 more
wiley +1 more source
Therapeutic potential of natural products in cancer immunotherapy: Advances and challenges
This review systematically outlines the mechanisms underlying tumour immunotherapy resistance and elucidates the role of natural products in enhancing therapeutic efficacy as immunomodulatory adjuvants. Abstract Immunotherapy has emerged as a clinically pivotal approach in cancer treatment, but its application remains limited to a small subset of ...
Rao Hu +6 more
wiley +1 more source
Chronic myelogenous leukemia in sickle cell/beta 0 -thalassemia
Sickle cell/beta 0 -thalassemia (S/β0 -thal) is a compound heterozygous state for βS and β0 thalassemia. There are rare reported cases of patients with sickle cell disease who developed hematological neoplasms including myeloid and lymphoid conditions ...
Maha M Sallam +3 more
doaj +1 more source
Long Non‐Coding RNA, Like NEAT1 and MALAT1, in Asthma: Mechanisms and Therapeutic Potential
Long non‐coding RNA, like NEAT1 and MALAT1, is emerging as a regulator of asthma‐related inflammation, airway remodelling, viral responses and cell death pathways, and are promising targets for future therapeutics. ABSTRACT Asthma affects millions worldwide. Long non‐coding RNA (lncRNA) are emerging as important factors in the pathophysiology of asthma
Ashlyn Poole +4 more
wiley +1 more source
Unlike generalized mTOR inhibitors, Torin‐1 uniquely drives compensatory upregulation of TIM‐3 on human NK cells, shielding them from immunosuppression while concurrently inhibiting glioblastoma (GBM) growth. Selecting or preconditioning ex vivo NK cell products for high TIM‐3 expression can offer a combination strategy for adoptive cell therapy in GBM.
Yuning Liu +11 more
wiley +1 more source

